Covertness in the Near Field: Maximizing the Covert Region with FDA
Fatemeh Lotfi, Stefan Roth, Anas Chaaban, Aydin Sezgin

TL;DR
This paper explores near-field FDA-based transmission strategies to enhance covert communication in 6G networks by expanding the covert region and reducing detectability through advanced beamforming that considers both distance and angle.
Contribution
It introduces near-field FDA beamforming techniques that manipulate beampatterns in both distance and angle, improving covert communication security in near-field scenarios.
Findings
Significantly reduces the non-covert region around the legitimate user.
Outperforms conventional phased arrays in shrinking the non-covert area.
Expanding the covert region as the number of antennas increases.
Abstract
Covert communication in wireless networks ensures that transmissions remain undetectable to adversaries, making it a potential enabler for privacy and security in sensitive applications. However, to meet the high performance and connectivity demands of sixth-generation (6G) networks, future wireless systems will require larger antenna arrays, higher operating frequencies, and advanced antenna architectures. This shift changes the propagation model from far-field planar-wave to near-field spherical-wave which necessitates a redesign of existing covert communication systems. Unlike far-field beamforming, which relies only on direction, near-field beamforming depends on both distance and direction, providing additional degrees of freedom for system design. In this paper, we aim to utilize those freedoms by proposing near-field Frequency Diverse Array (FDA)-based transmission strategies…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMedical Malpractice and Liability Issues · Pharmacovigilance and Adverse Drug Reactions · Ethics in Clinical Research
